Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine

Luijkx, Thomas A.; Dijken, Harry van; van, Cécile A. C. M.; Dobbelsteen, Germie van den

doi:10.1016/j.vaccine.2005.10.003

Cited by 12 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar observations were reported by Moe et al after sequential immunization of mice and guinea pigs with OMVs and microvesicles from different heterologous meningococcal strains (15). Luijkx et al have also studied a primeboost strategy with heterologous OMV vaccines in mice (12). Their conclusion was that a specific priming rather than a specific boosting with monovalent OMVs resulted in a significant rise in the serosubtype-specific immune response against a weakly immunogenic PorA.…”

Section: Discussionsupporting

confidence: 74%

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

Sandbu

Feiring

Oster

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

MenBvac and MeNZB are safe and efficacious vaccines against serogroup B meningococcal disease. MenBvac is prepared from a B:15:P1.7,16 meningococcal strain (strain 44/76), and MeNZB is prepared from a B:4:P1.7-2,4 strain (strain NZ98/254). At 6-week intervals, healthy adults received three doses of MenBvac (25 g), MeNZB (25 g), or the MenBvac and MeNZB (doses of 12.5 g of each vaccine) vaccines combined, followed by a booster 1 year later. Two-thirds of the subjects who received a monovalent vaccine in the primary schedule received the other monovalent vaccine as a booster dose. The immune responses to the combined vaccine were of the same magnitude as the homologous responses to each individual vaccine observed. At 6 weeks after the third dose, 77% and 87% of the subjects in the combined vaccine group achieved serum bactericidal titers of >4 against strains 44/76 and NZ98/254, respectively, and 97% and 93% of the subjects achieved a fourfold or greater increase in opsonophagocytic activity against strains 44/76 and NZ98/254, respectively. For both strains, a trend of higher responses after the booster dose was observed in all groups receiving at least one dose of the respective strain-specific vaccine. Local and systemic reactions were common in all vaccine groups. Most reactions were mild or moderate in intensity, and there were no vaccine-related serious adverse events. The safety profile of the combined vaccine was not different from those of the separate monovalent vaccines. In conclusion, use of either of the single vaccines or the combination of MenBvac and MeNZB may have a considerable impact on the serogroup B meningococcal disease situation in many countries.

show abstract

Section: Discussionsupporting

confidence: 74%

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

Sandbu

Feiring

Oster

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Other studies with multivalent PorA vaccine confirm this observation [10], [36]. Priming with monovalent OMV from less immunogenic PorA subtypes before immunization with the multivalent vaccine may solve this issue [45]. A recent study with mice and rabbits confirmed that NonaMen vaccine from the improved process induces broad immunogenicity without related toxicity or pathology [36].…”

Section: Discussionmentioning

confidence: 89%

Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis

et al. 2013

View full text Add to dashboard Cite

An improved detergent-free process has been developed to produce vaccine based on native outer membrane vesicles (NOMV) against Neisseria meningitidis serogroup B. Performance was evaluated with the NonaMen vaccine concept, which provides broad coverage based on nine distinct PorA antigens. Scalable aseptic equipment was implemented, replacing undesirable steps like ultracentrifugation, inactivation with phenol, and the use of preservatives. The resulting process is more consistent and gives a higher yield than published reference processes, enabling NOMV production at commercial scale. Product quality met preliminary specifications for 9 consecutive batches, and an ongoing study confirmed real-time stability up to 12 months after production. As the NOMV had low endotoxic activity and induced high bactericidal titres in mice, they are expected to be safe and effective in humans. The production process is not limited to NonaMen and may be applicable for other N. meningitidis serogroups and other gram-negative pathogens. The current results therefore facilitate the late-stage development and clinical evaluation of NOMV vaccines.

show abstract

“…For these reasons, vaccines containing outer membrane vesicles have been created for a number of Gram negative bacteria, including Neisseria meningitidis, Vibrio cholerae, and Helicobacter pylori (26)(27)(28). Vaccination with outer membrane vesicles has been appeared to elicit mainly serosubtype specific bactericidal antibodies against multiple bacterial antigens; in any case, some cross-reactivity increasing after three doses of immunization in adults has been shown in some studies (29). Although lipopolysaccharide is a toxic molecule in vesicles, it acts as a potent adjuvant.…”

Section: Discussionmentioning

confidence: 99%

Extraction and Biological Evaluation of the Membrane Vesicles of Mycobacterium tuberculosis (CRBIP7.11) as Adjuvant and Vaccine Candidate

Daliri

Kafil

Aghazadeh

et al. 2017

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Membrane vesicles are non-viable structures released by pathogenic bacteria. They contain numerous antigenic materials from the bacterial outer membrane, making them attractive targets for use as vaccine antigens. The membrane vesicles are related to the virulence because of their capacity to concentrate immunomodulatory molecules and toxins. Objective: In the present study, we examined the membrane vesicles of Mycobacterium tuberculosis as adjuvant and vaccine candidate. Methods: Mycobacterium tuberculosis standard strain CRBIP7.11 was cultured at 37°C in Loewenstein Johnson (LJ) media for 3-4 weeks. To confirm the species, standard microbiological and biochemical tests were performed. After preparation of membrane vesicles, the amount of protein in membrane vesicles was measured by SDS-PAGE and Nanodrop. To analyze the integrity and morphology of extracellular vesicles, transmission electron microscopy was used. The lipopolysaccharide was determined using the Limulus Amebocyte Lysate (LAL) kit. Results: The total mass of vesicular fraction was 4.8 mg. SDS-PAGE showed protein bands in the approximate regions of 35, 40, 70, and 90 kDa. The amount of membrane vesicles total protein was 1.26 and 1.29 mg/mL. Transmission electron microscopy analysis of pellets revealed that the extracted vesicles are 50-200 nm in size. Also, LaL test showed negative results (values were less than 300 IU). Conclusions:The results of the present study give important evidence that actively released mycobacterial vesicles are delivery instruments for immunologically active molecules involved in mycobacterial virulence.

show abstract

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine

Cited by 12 publications

References 46 publications

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis

Extraction and Biological Evaluation of the Membrane Vesicles of Mycobacterium tuberculosis (CRBIP7.11) as Adjuvant and Vaccine Candidate

Contact Info

Product

Resources

About